BPC September 03 update

NeuroPharma IMPL -19% FDA approval of nasal spray for migraines; Innate Pharma IPHA +47% Phase 2 abstract to be presented at ESMO

Price and Volume Movers

NeuroPharma, Inc. (NASDAQ: IMPL) announced the FDA approval of TRUDHESA, a nasal spray for the acute treatment of migraine in adults. The new drug bypasses potential absorption issues, offering rapid relief without injection or infusion, even when administered hours after the onset of a migraine attack. The commercial launch of TRUDHESA is planned for early October 2021. Shares closed down 19% at $18.62.

Innate Pharma SA (NASDAQ: IPHA) announced that AstraZeneca will present a late-breaker abstract on the COAST Phase 2 trial, including Innate's monalizumab, and oleclumab, an anti-CD73 monoclonal antibody, to treat non-small cell lung cancer (NSCLC). The presentation will take place at the ESMO 2021 Virtual Congress on September 17, 2021. In anticipation of the presentation, shares closed up 47% at $6.15.

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) announced that the FDA has acknowledged that it received the supplemental New Drug Application (sNDA) for Qelbree for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults. The sNDA is now considered filed, with a PDUFA date of April 29, 2022.

Forte Biosciences Inc. (NASDAQ: FBRX) continued to trade lower following the released topline data yesterday from its Phase 2 trial of FB-401 for the treatment of atopic dermatitis. The trial failed to meet its primary endpoint. Shares closed down 83% at $5.04.

Jaguar Health, Inc. (NASDAQ: JAGX) announced that it will effect a reverse stock split of its common stock at an exchange ratio of 1-for-3, on Wednesday, September 8, 2021. Shares are trading down 9% at $1.06 after hours.

Advancers

CompanyPriceChange
CRVS
Corvus Pharmaceuticals Inc.
$5.32+3.06  +135.40%
IPHA
Innate Pharma S.A.
$8.10+2.35  +40.87%
CYDY
Cytodyn Inc
$2.01+0.37  +22.56%
SURF
Surface Oncology Inc.
$7.10+1.09  +18.14%
ATNM
Actinium Pharmaceuticals Inc. (Delaware)
$7.83+1.15  +17.22%
EVLO
Evelo Biosciences Inc.
$8.34+1.03  +14.09%
MGTA
Magenta Therapeutics Inc.
$7.79+0.92  +13.39%
CNTB
Connect Biopharma Holdings Limited
$23.06+2.51  +12.21%
TRVN
Trevena Inc.
$1.36+0.14  +11.48%
FULC
Fulcrum Therapeutics Inc.
$30.83+3.14  +11.34%

Decliners

CompanyPriceChange
PTGX
Protagonist Therapeutics Inc.
$17.53-28.6  -62.00%
TCRR
TCR2 Therapeutics Inc.
$9.99-5.73  -36.45%
ELYM
Eliem Therapeutics Inc
$18.77-5.27  -21.92%
JANX
Janux Therapeutics Inc.
$27.39-6.96  -20.26%
ICVX
Icosavax Inc.
$33.06-6.4  -16.22%
IPSC
Century Therapeutics Inc.
$24.76-4.49  -15.35%
GRTS
Gritstone bio Inc.
$11.50-2.04  -15.07%
VERV
Verve Therapeutics Inc.
$59.88-9.99  -14.30%
INAB
IN8bio Inc.
$7.00-1.09  -13.47%
TNYA
Tenaya Therapeutics Inc.
$20.85-3.2  -13.31%

Pipeline Database Updates

Drug Price Stage Catalyst Market Cap

IMPL – Impel NeuroPharma Inc.
TRUDHESA (Dihydroergotamine)
Migraine

$14.44
+0.25  +2%
Approved FDA Approval announced September 3, 2021.
$281.7 million

PFE – Pfizer Inc.
Comirnaty (BNT162b2)
COVID-19 Vaccine (Booster)

$43.89
-0.58  -1%
BLA Filing sBLA has been submitted. Advisory committee scheduled September 17, 2021.
$246.1 billion

PLRX – Pliant Therapeutics Inc.
PLN-74809
Idiopathic pulmonary fibrosis

$18.24
-0.76  -4%
Phase 2a Phase 2a PET positive interim data results released September 7, 2021.
$655.5 million

SUPN – Supernus Pharmaceuticals Inc.
Qelbree - SPN-812 (adult)
ADHD

$27.28
+0.09  +0%
PDUFA sNDA has been filed on September 3, 2021 with a PDUFA date of April 29, 2022.
$1.4 billion